Raising blood levels of AAT with augmentation therapy prevents T1DM development, prolongs islet allograft survival [18], increases insulin release capacity [31], and inhibits pancreatic B-cell apoptosis [32]. The gene discussed is SERPINA1; the disease is type 1 diabetes mellitus.